文献速递瓣膜外科

去细胞Matrix P生物假体在Ross手术中肺动脉瓣替换的长期结果

Long-term results after the Ross procedure with the decellularized AutoTissue Matrix P® bioprosthesis used for pulmonary valve replacement.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

该研究回顾了2002至2010年间492例成人Ross手术患者,使用去细胞Matrix P假体进行肺动脉瓣替换,平均随访7.7年。结果显示Matrix P假体相关功能障碍和再次干预发生率高,远期生存受损,作者不建议在成人Ross手术中使用该假体。

要点

  • Matrix P假体远期肺动脉瓣再次手术率高,5年、10年、12.5年免于再手术率分别为76.2%、58.6%、53.4%。
  • 该假体结构衰败导致右心衰竭和再次干预,远期生存率低于预期。
  • 不建议在成人Ross手术中使用Matrix P假体进行肺动脉瓣替换。

核心结论

  • Matrix P假体在Ross手术中远期超声结果不佳,肺动脉瓣结构衰败导致再次手术/干预率高,远期生存受损,不推荐用于成人Ross手术的肺动脉瓣替换。

研究设计与样本

  • 回顾性分析2002至2010年间在本机构接受Ross手术并使用Matrix P假体的492例成人患者,平均年龄57.2±10.6岁(范围21-73岁),前瞻性收集数据,共3617.3患者年,平均随访7.7±4.3年。

主要发现

  • 住院死亡率为3.9%(n=19);随访期间121例死亡,5年、10年、12.5年生存率分别为82.8±1.7%、70.4±2.3%、62.4±2.9%。
  • 超声心动图显示Matrix P假体相关功能障碍和右心衰竭发生率高;150例Matrix P和48例自体移植物需初次再次手术/干预。
  • 免于肺动脉瓣再次手术率在5年、10年、12.5年分别为76.2±2.1%、58.6±2.9%、53.4±3.4%;自体移植物功能及左心室功能与既往报道相似,免于自体移植物再次手术率分别为91.8±1.4%、86.1±2.0%、86.1±2.0%。

临床怎么用

  • 在成人Ross手术中应避免使用Matrix P假体进行肺动脉瓣替换,并加强使用该假体患者的远期随访和超声监测。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Since 1967, the Ross procedure has been performed to treat aortic valve disease using homografts for pulmonary valve replacement. The decellularized Matrix P® prosthesis was developed to overcome (some) limitations of homografts. Until now, the long-term outcome data have been unavailable. METHODS: Between 2002 and 2010, the Ross procedures using the Matrix P prosthesis were performed in 492 adult patients (mean age 57.2 ± 10.6 years, range 21-73 years) at our institution. Patient data were prospectively collected and analysed (3617.3 patient-years, mean follow-up 7.7 ± 4.3 years). Completeness of follow-up at 1, 5 and 10 years was 98.4%, 94.5% and 91.0%, respectively. RESULTS: Hospital mortality was 3.9% (n = 19). During follow-up, 121 patients died resulting in a survival rate at 5, 10 and 12.5 years of 82.8 ± 1.7%, 70.4 ± 2.3% and 62.4 ± 2.9%, respectively. Echocardiography revealed a high incidence of relevant dysfunction of the Matrix P prosthesis and subsequent right ventricular failure. Primary reoperation/reintervention was necessary for 150 Matrix P and 48 autografts. Freedom from pulmonary valve reoperation at 5, 10 and 12.5 years was 76.2 ± 2.1%, 58.6 ± 2.9% and 53.4 ± 3.4%, respectively. The autograft function and the left ventricular function showed similar results as previously reported with a freedom from autograft reoperation at 5, 10 and 12.5 years of 91.8 ± 1.4%, 86.1 ± 2.0% and 86.1 ± 2.0%, respectively. CONCLUSIONS: The Matrix P prosthesis used for the right ventricular outflow tract reconstruction in the Ross procedure showed unfavourable long-term echocardiographic results with a high rate of reoperation/reintervention for structural pulmonary valve failure. As a consequence, long-term survival of this patient cohort was impaired. Based on these findings, the use of the Matrix P prosthesis for pulmonary valve replacement for Ross procedures in adults should not be recommended.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Christ T, Paun AC, Grubitzsch H, et al. Long-term results after the Ross procedure with the decellularized AutoTissue Matrix P® bioprosthesis used for pulmonary valve replacement. Eur J Cardiothorac Surg. 2019. PMID: 30508165. doi:10.1093/ejcts/ezy377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。